Skip to main content

Drug Interactions between Lamictal and olanzapine / samidorphan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

lamoTRIgine OLANZapine

Applies to: Lamictal (lamotrigine) and olanzapine / samidorphan

Coadministration with olanzapine may slightly decrease the plasma concentrations of lamotrigine. The mechanism of interaction has not been described. In 16 healthy male volunteers, addition of olanzapine (15 mg once daily) decreased the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of lamotrigine (200 mg once daily) by 20% and 24%, respectively, compared to administration of lamotrigine alone in 12 healthy male volunteers. These alterations are unlikely to be of clinical significance. In another study, olanzapine 5 mg had no effect on the Cmax and AUC of lamotrigine (25 mg daily for 5 days, then 50 mg daily for 13 days) in 14 healthy volunteers, but significantly increased the mean time to reach peak plasma concentration (Tmax) of lamotrigine from 1.9 to 4.0 hours. This effect may be attributable to the anticholinergic properties of olanzapine. Mild sedation was the only adverse effect reported during lamotrigine and olanzapine coadministration. Lamotrigine has no effect on the pharmacokinetics of olanzapine.

References (2)
  1. (2001) "Product Information. Lamictal (lamotrigine)." Glaxo Wellcome
  2. Jann MW, Hon YY, Shamsi SA, Zheng J, Awad EA, Spratlin V (2006) "Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers." Pharmacotherapy, 26, p. 627-33

Drug and food interactions

Moderate

lamoTRIgine food

Applies to: Lamictal (lamotrigine)

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (4)
  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
Moderate

OLANZapine food

Applies to: olanzapine / samidorphan

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (4)
  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer